Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04647656 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome

Study acronym: HBOTpCOVID
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 27, 2021 to Dec 31, 2027v5 Show 4 more changesShow less
    • Start date: Dec 14, 2020 to Jun 1, 2023
    • Trial status: Completed to Recruiting
    • Study completion date: Jan 10, 2022 to Dec 31, 2027
    • Site details revised
  2. Re-verified, no change to tracked fieldsv4
  3. Secondary endpoints: details revised at 4 of 15 entriesv3
  4. Trial status: Not Yet Recruiting to Completedv2 Show 8 more changesShow less
    • Enrollment target: estimated 70 to confirmed 91
    • Primary completion date changed from estimate of Jan 1, 2022 to Dec 27, 2021
    • Study completion date changed from estimate of Jan 1, 2023 to Jan 10, 2022
    • Start date changed from estimate of Jan 1, 2021 to Dec 14, 2020
    • Secondary endpoints: details revised at 6 of 15 entries
    • Study description expanded, about 7 words
    • Site contact updated
    • Eligibility criteria expanded, about 3 words
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome
Trial Details
NCT Number NCT04647656
Lead Sponsor Assaf-Harofeh Medical Center
Conditions
(from sponsor)		 Covid19, Neurocognitive Dysfunction
Related terms Cognition Disorders, COVID-19
Enrollment 91 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov